Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492881 | 0.81 | CASP3 (0.31) | — | |
| SCHEMBL5403207 | 0.80 | PEPD (0.31) | PEPD | |
| SCHEMBL28178861 | 0.77 | DPP4 (0.33) | PEPD | |
| SCHEMBL3275668 | 0.77 | PDK2 (0.36) | PEPD | |
| SCHEMBL5411613 | 0.77 | ELANE (0.34) | PEPD | |
| SCHEMBL5413986 | 0.76 | PREP (0.35) | — | |
| SCHEMBL3332146 | 0.73 | TSHR (0.36) | PEPD | |
| SCHEMBL3332688 | 0.72 | KDM4E (0.46) | — | |
| SCHEMBL5406487 | 0.72 | RAB9A (0.30) | — | |
| SCHEMBL3328327 | 0.71 | KDM4E (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | CNR2 257/4885PEPD 855/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | CNR2 85/4885PEPD 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.